Division of Services and Intervention Research, National Institute of Mental Health, 6001 Executive Blvd, Bethesda, MD 20892, USA.
Circulation. 2010 Mar 23;121(11):1329-37. doi: 10.1161/CIRCULATIONAHA.109.901256. Epub 2010 Mar 8.
Stimulants are widely used to treat children with attention deficit/hyperactivity disorder and may increase the risk for sudden cardiac death (SCD). We examined the cost-effectiveness of pretreatment screening with ECG for reducing SCD risk in children diagnosed with attention deficit/hyperactivity disorder who are candidates for stimulant medication. Method and Results- We constructed a state-transition Markov model with 10 annual cycles spanning 7 to 17 years of age. Taking a societal perspective, we compared the cost-effectiveness of 3 screening strategies: (1) performing a history and physical examination with cardiology referral if abnormal (current standard of care); (2) performing a history and physical examination plus ECG after negative history and physical examination, with cardiology referral if either is abnormal; and (3) performing a history and physical examination plus ECG, with cardiology referral only if ECG is abnormal. Children identified with SCD-associated cardiac abnormalities would be restricted from stimulants and from playing competitive sports. The expected incremental cost-effectiveness over strategy 1 was $39,300 and $27,200 per quality-adjusted life-year for strategies 2 and 3, respectively. Monte Carlo simulation found that the chance of incremental cost-effectiveness was 55% for strategy 2 and 71% for strategy 3 (willingness to pay < or =$50,000 per quality-adjusted life-year). Both strategies 2 and 3 would avert 13 SCDs per 400,000 children seeking stimulant treatment for ADHD, for a cost of $1.6 million per life for strategy 2 and $1.2 million per life for strategy 3.
Relative to current practice, adding ECG screening to history and physical examination pretreatment screening for children with attention deficit/hyperactivity disorder has borderline cost-effectiveness for preventing SCD. Relative cost-effectiveness may be improved by basing cardiology referral on ECG alone. Benefits of ECG screening arise primarily by restricting children identified with SCD risk from competitive sports.
兴奋剂被广泛用于治疗患有注意缺陷多动障碍的儿童,可能会增加心脏性猝死 (SCD) 的风险。我们研究了心电图 (ECG) 预处理筛查对减少候选兴奋剂治疗的注意缺陷多动障碍儿童的 SCD 风险的成本效益。
我们构建了一个具有 10 个年度周期的状态转移马尔可夫模型,涵盖了 7 至 17 岁的年龄。从社会角度出发,我们比较了 3 种筛查策略的成本效益:(1)进行病史和体检,如果异常则请心脏病专家会诊(当前的标准护理);(2)进行病史和体检,若病史和体检正常,则进行 ECG,若任何一项异常,则请心脏病专家会诊;(3)进行病史和体检以及 ECG,仅在 ECG 异常时请心脏病专家会诊。如果发现患有与 SCD 相关的心脏异常的儿童,他们将被限制使用兴奋剂和参加竞技运动。与策略 1 相比,策略 2 和策略 3 的增量成本效益分别为 39300 美元和 27200 美元/质量调整生命年。蒙特卡罗模拟发现,策略 2 的增量成本效益的机会为 55%,策略 3 的机会为 71%(意愿支付<或=50000 美元/质量调整生命年)。对于寻求治疗 ADHD 的 400000 名儿童中的每 400000 名儿童,这两种策略都会预防 13 例 SCD,策略 2 的治疗费用为每例生命 160 万美元,策略 3 的治疗费用为每例生命 120 万美元。
与当前实践相比,在对患有注意缺陷多动障碍的儿童进行治疗前的病史和体检中增加心电图筛查,对于预防 SCD 具有边缘成本效益。通过仅基于 ECG 来进行心脏病学转诊,可以提高相对成本效益。ECG 筛查的益处主要来自限制患有 SCD 风险的儿童参加竞技运动。